Category Archives: touc

Nasdaq 100 Watch List

Below are the Nasdaq 100 companies that are within 20% of the 52-week low. This list is strictly for the purpose of researching whether or not the companies have viable business models or are about to go out of business. These companies are deemed highly speculative unless otherwise noted. -Touc
Symbol Company Name Trade P/E EPS (ttm) Yield P/B Pct from Yr Low

FSLR

First Solar

112.39

14.98

7.50

N/A

4.12

11.39%

GILD

Gilead Sci.

46.08

17.82

2.59

N/A

7.31

13.44%

GENZ

Genzyme

54.38

31.00

1.75

N/A

1.90

15.48%

APOL

Apollo Grp

61.19

14.72

4.16

N/A

6.50

15.91%

ERTS

E A

16.77

N/A

-4.06

N/A

2.13

17.77%

ATVI

Activision

10.365

42.31

0.245

N/A

1.19

19.55%

Investment Observation: Gilead Sciences (GILD) at $45.52

In my August 3o, 2009 article titled "Reviewing the Stock Analysts," I pointed out a book that I felt would advance your ability to analyzing individual stocks much better than whatever method that you might be using. In the article that I posted on August 30th, I stated that I'm convinced that if you buy the book Quest For Value you would have made a wise investment.

The only reason that I'm convinced that Quest For Value is useful is due to the third party examination of the performance of the approach as applied by Matrix USA. On a consistent basis, the economic value added (EVA) method was attributable to Matrix USA beating all other stock analysts for buying and selling stocks.

Now, in the most recent issue of Fortune Magazine dated January 18, 2010, Geoff Colvin reiterates that using the economic value added (EVA) approach is resoundingly effective at discerning quality stocks without the ability of corporations to tweak or fudge the financials through generally accepted accounting principles.

The punchline to the Colvin article is that of the three top quality companies based on the EVA model, Gilead Sciences (GILD) is among them. GILD happens to be one of the Nasdaq 100 companies on our most recent watch list. On October 23, 2009, I indicated that based on the Coppock Curve, GILD would be among the best companies to investigate for a potential purchase. I am reiterating the belief that GILD is worthy of investigating since it has not varied by much since my last look at the company. -Touc

related articles:

Speculative Observation: Electronic Arts Inc. (ERTS) at $16.74

In after hours-trading Electronic Arts (ERTS) fell over 8% on news that the company had lower sales, wider annual loss and had to reduce full year guidance. According to Yahoo!Finance, ERTS "...develops, markets, publishes, and distributes video game software and content."

This is the perfect example of a company that was thought to have it all and possibly be recession proof. After all, 13-34 year old males were going to buy and play video games regardless of the economic environment. ERTS' stock price and company earnings, like much of the "conventional" wisdom the exists about the markets, proved to defy much of the logic.

Personally, I don't track earnings estimates since the concept of earnings is more or less an accounting interpretation that conveniently fits a corporate strategy to show profits or losses as needed. The concept of estimates of future expectations tied to the idea of earnings is a kind of mental gymnastics that I don't have the patience for. However, as part of the New Low Observer team, it is my primary responsibility to track Nasdaq 100 companies that have compelling price action at, or near, a new low.

ERTS last appeared on the New Low Observer on December 11, 2009. At the time, ERTS was within 13% of the new low after falling from the lofty levels of $61 in 2007. After being on our Nasdaq 100 Watch List for only a couple of weeks, ERTS rose 15.82% in 26 days.

ERTS hasn't had luck recovering from it's market doldrums. However, for astute market participants with a penchant for speculation, this stock may provide exceptional opportunities. When ERTS hit the ultimate low of $14.24 ( March 9, 2009) it was in the throes of a market meltdown. In this instance (March 2009 low), we could chalk up the stock price performance primarily to the "adverse" conditions of the market. This means that the price action didn't reflect the truly dire conditions of the company specifically.

Now, as we see the stock getting pummeled in after-hours, we can find comfort in knowing that investors have had the opportunity to better gauge the conditions of the company and are about to price in the worst that is yet to come. One matter that is tremendously bothersome to me regarding the situation at ERTS is that the company is trying to bury the bad news with a flood of press releases. This annoys me to no end and indicates that the company has more to hide than reveal in the latest earnings report.

Although ERTS is in free fall mode, I recommend that potential speculators jump on the best information resources at your disposal (Value Line, Morningstar and Mergent's etc.) and verify whether or not this company truly has a viable business model. My suspicion is that ERTS is an opportunity that is waiting to be capitalized upon after considerable assessment of risk tolerance and due diligence has been done. Be mindful of the prospect that this company could test the long term support level of $10. Only put money that you're willing to lose towards this "special" situation. -Touc

Nasdaq 100 Watch List

Below are the Nasdaq 100 companies that are within 20% of the 52-week low. This list is strictly for the purpose of researching whether or not the companies have viable business models or are about to go out of business. These companies are deemed highly speculative unless otherwise noted. -Touc

Symbol Name Trade P/E EPS (ttm) Yield P/B Pct from Yr Low

GENZ

Genzyme

49.01

27.94

1.75

N/A

1.73

4.08%

GILD

Gilead

43.27

16.73

2.59

N/A

7.00

6.52%

APOL

Apollo

60.58

16.15

3.75

N/A

8.18

14.76%

CEPH

Cephalon

62.42

17.25

3.62

N/A

2.19

18.78%

The Language of Wall Street

  • The rich man does not know who is his friend.
  • A man gets no thanks for what he loses that play.
  • They who live in a worry invite death in a hurry.
  • Soft words and hard arguments catch the investor.
  • Put your eggs in one basket and watch the basket.
  • Every time the sheep bleats it loses a mouthful.
  • The rich are meanest when they buy small things.
  • The rich man is apt to be more generous than just.
  • He swears who is accustomed to his own false words.
  • Money easily made, easily goes; easy come, easy go.
  • If you do not hear reason, she will wrap your knuckles.
  • He who prates of his wisdom doth but conceal an ass.
  • Provide for the worst; the best will take care of itself.
  • It is an old maxim that accidents usually help the Bears.
  • Lend money without bond and you but make an enemy.
  • The advice of successful men only is worth application.
  • A man with long hair is generally rash and impetuous.
  • A man must make his opportunity as often as he finds it.
  • Things in motion sooner catch the eye than what not stirs.
  • He who sells what isn’t his, must buy it back or go to prison.
  • Sell and borrow only those stocks which have a wide market.
  • Some had rather guess that much then take pains to learn a little.
  • Men of wit and facts never need be driven to indirect courses.
  • To estimate a man’s wealth, divide the gossip estimates by four.
  • To grasp an opportunity with a firm decision marks an able man.
  • After advancing markets, and prices waiver, lower prices will come.
  • When prices are high, or there is a declining tendency, sell on rallies.
  • Much money made before 20 is apt to be lost in the reign of plenty.
  • He is rich enough to as no debts, and young enough who has health.
  • “Early information” and a big bank account will be the ruin of any man.
  • Moderate riches will carry you; if you have more, you must carry them.
  • The success of a manipulated market depends largely on sustained activity.
  • It is idle to wait for your ship to come in unless you have sent one out.
  • When prices close week without support, a rally would be in order next morning.
  • He who takes no care of little things will not have the care of great ones.
  • When prices are low, or there is an advancing tendency, buy fair concessions.
  • A lordly taste makes a beggar’s purse; a champagne appetite but a purse for beer.

Source: Nelson, Samuel A. The ABC of Stock Speculation. S.A. Nelson. 1902

A View on the "Buy Low, Sell High" Concept

As the old investment adage goes, "buy low and sell high." However, the act of buying low has a few complications which hasn't been easily resolved. One problem is knowing when a stock's price is actually at a low price or not. Most people confuse the absolute level of a stock price with being low. For example, if a stock is selling for $2 then a person might think that this is a great price to acquire the shares. However, if $2 is the new high for the price and one year ago the old low was $0.25 then $2 is actually very high.

One way that the New Low Observer (NLO) has managed to isolate whether a stock is at a low price is by waiting until the stock is within 20% of the new low. This approach isn't a cure for what ails the average investor. However, it does allow average market participants the opportunity to investigate quality companies for potential price increases. The new low of a stock automatically implies that value has been created especially if the company in question can survive as a going concern. This is counter to most information coming out of the Wall Street media machine. Typically, analysts on Wall Street recommend stocks that have risen far above the low before initiating coverage on a stock.

While there are 4336 individual stocks that can be bought on American stock exchanges, NLO has determined that there are basically only 383 companies that warrant your attention. The first group of companies are known as the Dividend Achievers (excel list of companies). These 283 companies are tracked by Mergent's based on their ability to increase their dividends every year for over 10 years in a row as a minimum requirement. It goes without saying that these companies pay some kind of dividend with yields that range from over 5% to less than 1%.

The second major group of companies tracked by NLO are the constituents of the Nasdaq 100. In our earlier forms as Dividend Inc. and Arti Invest, we believed that only Dividend Achievers were worth tracking since the dividend payment was verifiable regardless of "accounting" inconsistencies that are commonly found with "other" companies. The performance of this approach has been well documented and proven quite profitable.

However, the reality of the stock market dictates that we widen our perspective on companies that might afford significant opportunity with reduced risk. We, at NLO, decided that the Nasdaq 100 was the next obvious choice. After all, most mutual funds are bound to invest in these companies regardless of their unwillingness to pay dividend income. Additionally, companies in the Nasdaq 100 have solid reputations with higher prospects for growth over the long term.

One recent example of the benefit of tracking and research companies posted on NLO, as opposed to those from the Wall Street media machine, is Stericycle (SRCL). SRCL last appeared on our Nasdaq 100 watch list on October 30th. After being on our watchlist since the July 24th initiation of our website, SRCL has managed to climb from the low of $47.76 to the most recent high of $58. This is an increase of 18% from the July low and 21% from the October low and 11.54% from the breakout above our watch list range of being within 20% of the 52-week low.

NLO can be easily contrasted with the recent short-term buy recommendation placed on SRCL by Zack's Investment Research. In a tiny blurb issued today, Zack's Investment Research indicated that SRCL's stock had been in an oversold state based on the stochastics which indicated or implied that the stock was likely to go higher in the near term.

Unfortunately, offering up information about SRCL long after the stock has risen by at least 18% doesn't serve the small investor. After all, isn't the mantra "buy low, sell high?" It is strange to note that no analysts covering SRCL (in the following link) issued a buy recommendation on the stock after February 2004, even though there has been tremendous opportunities to buy in October 2008, February 2009, May 2009 and October 2009.

SRCL is only one of the companies that has been on the NLO Nasdaq 100 Watchlist that performed exceptionally well after getting off the list. Below are other Nasdaq 100 companies and their performance since getting within 20% of the new low:

It should be noted that the above companies are almost the entire list of companies that have appeared on the Nasdaq 100 Watch List. So far, this implies that quality Nasdaq companies could be investigated for speculative opportunities near the new low. Hopefully this approach can provide a reasonable approach to buying low with the prospect of selling higher. Follow along with us as we continue to investigate the speculative opportunities of the Nasdaq 100. -Touc

Nasdaq 100 Watch List

Below are the Nasdaq 100 companies that are within 20% of the 52-week low. This list is strictly for the purpose of researching whether or not the companies have viable business models or are about to go out of business. These companies are deemed highly speculative unless otherwise noted. -Touc

Symbol

Name Trade P/E EPS (ttm) Yield P/B % Yr Low

GENZ

Genzyme Corporation

48.50

27.65

1.75

N/A

1.68

2.99%

GILD

Gilead Sciences, Inc.

43.00

16.63

2.59

N/A

6.87

5.86%

APOL

Apollo Group, Inc.

59.27

15.80

3.75

N/A

7.81

12.28%

CEPH

Cephalon, Inc.

59.88

16.55

3.62

N/A

2.08

13.95%

Nasdaq 100 Watch List

Below are the Nasdaq 100 companies that are within 20% of the 52-week low. This list is strictly for the purpose of researching whether or not the companies have viable business models or are about to go out of business. These companies are deemed highly speculative unless otherwise noted.

Symbol

Name Price P/E EPS Yield P/B

% from Low

GENZ

Genzyme

48.78

27.81

1.75

N/A

1.68

3.59%

GILD

Gilead

42.83

16.56

2.59

N/A

6.90

5.44%

APOL

Apollo Grp

58.40

15.57

3.75

N/A

7.67

10.63%

CEPH

Cephalon

59.04

16.32

3.62

N/A

2.05

12.35%

ERTS

EA

16.72

N/A

-4.06

N/A

2.02

17.42%

ILMN

Illumina

27.88

38.78

0.72

N/A

3.40

19.71%

BIIB

Biogen

50.07

16.76

2.99

N/A

2.18

19.93%

Citigroup (C) Continues to Struggle

Below is a second look at an article that I published back in November 2008. This lays bare the extent of the problems faced by Citigroup. I hope anyone interested in Citigroup finds this article helpful. We can only hope that the Citi situation doesn't go the way of CreditAnstalt as described in previous articles. -Touc

The term that is the basis of all discussions in elementary economic modeling, especially when comparing two factors, is ceteris paribus. Ceteris paribus means "with other things the same" and represents the best guess as to what is likely to occur provided all thing remain unchanged. Let us take an overly simplistic view of the situation with Citigroup's government rescue plan and determine the potential outcome ceteris paribus.

According to the Wall Street Journal, in an article by David Enrich, the federal government has agreed to absorb $277 billion of $306 billion of losses that Citigroup has identified as "troubled" assets. Additionally, the Treasury is adding $20 billion on top of the $25 billion recently injected into Citigroup as part of the TARP plan. Remember, the $277 billion is separate from the $700 billion bailout package. Again, this current approach with Citi is counter to the early arguments that there needs to be a comprehensive solution, not an individual approach, to the bailouts after the fall of Fannie, Freddie, Lehman, Merrill and WaMu which spawned the TARP plan to begin with.

Now, let's look at only the off-balance sheet portion of Citigroup. The off-balance sheet portion is called an asset by Citi but isn't included on the books. The off-balance sheet items are valued at $1.23 trillion. I don't know why Citi wouldn't include these items on their balance sheet but if the U.S. government is any indication then the off-balance sheet is probably more like liabilities instead of assets.

If the government is going to front Citi $277 billion (a whopping 40% of the total TARP package for only one company) then that would leave $953 billion remaining on the off-balance sheet portfolio. If we split the $953 billion in half and conservatively assume this portion is "troubled" then we have a figure equal to $476.5 billion. Remember when Merrill Lynch auctioned off $30 billion of CDOs or "troubled" assets back in July 2008? Here's what Bloomberg.com said of that auction on July 29, 2008:

In yesterday's statement, Merrill said it agreed to sell $30.6 billion of collateralized debt obligations -- the mortgage-related bonds that have caused most of the firm's losses -- for $6.7 billion. The buyer is an affiliate of Lone Star Funds, a Dallas-based investment manager.

At the time, Merrill was only able to get $6.7 billion, a loss of 78% or $0.22 cents from every dollar originally invested. Therefore, my assumption of a 50% loss for Citi isn't so far fetched.

Ceteris paribus, this leaves Citi with at least $476.5 billion in losses to write down at some point in the future. This assumes that the economy remains in a slight recession, that earnings are the same, that the dividend for this company has been all but eliminated, that there are no further losses in the housing market. All things being equal, Citi is in for hard times. However, if we take 78% of the entire $953 billion then we get a total loss of $743 billion. A sum exceeding the amount of the entire TARP program even after a $277 billion direct injection to Citi from the government.

Clearly our government under Bush/Obama has severely underestimated the extent of how much damage has been done to our financial system. Along with the lack of knowledge that has been demonstrated, the only policy reaction is to have a blank check approach to dealing with the problem. This is what I meant when I said that chaos will ensue when and if Bank of America falls below $14.00.

Previous articles on Citigroup

Sources:

Sell AquaAmerica (WTR) at the Market

It is now time to recommend that AquaAmerica (WTR) be sold at the market. The stock has performed moderately since the research recommendation was issued on October 31, 2009. It is highly recommended that anyone who bought the stock based on my research should re-read the posting. Unfortunately, it was not possible to buy this stock at any price lower than the recommended date.

WTR's stock price has gone nothing but up since the recommendation. However, in the pursuit of "seeking fair profits" the returns that this stock has provided within the last 46 days say that it is necessary to consider alternative opportunities.

WTR was recommended when it was trading at $15.64. As of December 15, 2009, WTR was quoted at $17.28. This equals a return of 10%. Selling this stock now generates a return of 2x greater than the amount of the dividend yield. Additionally, the 10% gain exceeds the return on a 30-year treasury purchased on October 30, 2009 by 2.35x (if held to maturity.)

Those not interested in following through with my sell recommendation can feel comfortable knowing that WTR is a great long-term holding with a 10% cushion since our research recommendation of October 31, 2009.

As I have indicated in the purposes and function of this site, the goal is to:

  • maximize the annual yield of each trade.
  • reduce time between buying and selling of each stock.
  • exceed the annual yield of government guaranteed alternatives in each trade.

Research recommendations and investment observations are intended to be a starting point for investigating a quality company at a reasonable price. It is hoped that after doing the background research you can buy the stock at a lower price. Ideally the stock should be held in a tax deferred account and should not consist of less than 20% of your holdings. Personally, I prefer holding only 2-3 stocks at a time.

Sell recommendations are intended to deal with the short term reality of the market. The tracking of the Sell recommendations are the worst case scenario if you happen to have bought a stock at the time the research recommendation was made (please avoid making this mistake.) I aim for mediocrity in my returns, therefore I am happy with 9-12% annual gains. However, since codifying my approach to investing in 2005, I have had annual returns of 20% and above every year since.

It is always recommended that when selling a stock, one should not place stop orders, limit orders or orders after hours. This leaves the seller in the position of being vulnerable to the whims of the market makers. Instead, place your sell orders only as a market order during market hours. Some would complain that a market order during market hours might leave some profits on the table. However, I would rather leave some money on the table rather than have it taken away from me by the trades that are placed by institutions and market makers. Touc.

Reader Q & A

Question:
How do you determine that a stock price is undervalued?

Answer:
Because there are many ways to answer your question, I will first refer you to the standard responses to your questions. Please follow the link to Wikipedia's response to the question of when a stock is undervalued.
Our view at New Low Observer on undervaluation is that, after selecting companies that have a proven track record of dividend increases over many years, stocks are likelier to be fairly valued or undervalued as the price falls to a new 1 year low. Although this seems obvious, most investors are unwilling to investigate a stock that has a falling price history for fear of a continuation of the trend. The prevailing view is, "I will wait until the price starts moving up before investing in company X."

Our experience has been that, provided the company has a history of dividend payments (something that cannot be manipulated through accounting methods) and all other financials attributes being in order, the company is put on a list to be acquired at the earliest opportunity. A great book that summarizes our general approach is "Dividends Don't Lie" by Geraldine Weiss and the upcoming book "Dividends Still Don't Lie" by Kelly Wright. In these books the main idea is that quality stock tend to trade in a price range based on the dividend yield.

Question:

How do you define P/E ratio? What does it indicate?

Answer:
In addressing your question, I would refer you to Investopedia's response to what P/E means. The idea of price-earnings (P/E) ratios is pretty straightforward. However, we use the P/E ratio as a means to compare to the relative history of the stock in question. Some people like to compare the P/E ratio to the stock market indexes like the S&P 500 or Russell 2000 Index. A P/E above the indexes would signal that the stock might be overpriced, a P/E below the indexes might mean the stock is underpriced. However, we try to identify what the historical range for the stock is as compared to itself and not the index. If it is a quality company, there may exist a pattern of falling and rising price based on the historical tendency of the P/E ratio.

Question:

What does the one year low indicate?

Answer:
The new low of a company's price indicates that the stock in question needs to be examined for potential purchase. This is in stark contrast to recommending a stock that has increased in price by 30% to 50%. Just like shopping for clothes, food, or a computer, we gravitate towards lower prices and careful consideration of what we buy. We operate on the mantra of caveat emptor or buyer beware.

I hope the above explanations have peaked your interest in the basics of investing. Much of what we have pointed out about considering the purchase of stocks is rooted in being reluctant participants of a consumer society. However, we have transferred the same skills as consumers of liabilities to the acquisition of assets. I hope you have time to read the book "Dividends Don't Lie" through your local library (save some money) until the new book comes out next year. Touc.

Nasdaq 100 Watch List

The following are Nasdaq 100 members that are within 20% of the 52-week low:

  • Genzyme Corp. (GENZ) at $49.74 within 5.63%
  • Apollo Group (APOL) at $56.58 within 7.18%
  • Cephalon, Inc. (CEPH) at $58.94 within 12.16%
  • Electronic Arts (ERTS) at $16.11 within 13.13%
  • Gilead Sciences (GILD) at $46.42 within 14.28%
  • Ryanair Holdings (RYAAY) at $25.34 within 16.40%
  • Biogen Idec (BIIB) at $48.65 within 16.53%
  • Pharma. Prod. Dev. (PPDI) at $21.41 within 16.53%